
CBPO
Healthcare · Biotechnology · $4.63B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2021
EPS trend, 90 days to now · -100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 29, 2021 | After the close | 0.69 | 0.91 | +31.9% |
| Nov 24, 2020 | After the close | 1.28 | 1.39 | +8.6% |
| Aug 17, 2020 | After the close | 1.28 | 1.11 | -13.3% |
| May 20, 2020 | After the close | 1.38 | 1.56 | +13.0% |
| Mar 12, 2020 | Time not confirmed | 0.70 | 0.53 | -24.3% |
| Nov 13, 2019 | After the close | 0.88 | 1.40 | +59.1% |
| Aug 5, 2019 | After the close | 1.03 | 1.24 | +20.4% |
| May 10, 2019 | After the close | 0.98 | 1.11 | +12.7% |
| Mar 6, 2019 | After the close | 0.63 | 0.76 | +20.6% |
| Nov 1, 2018 | After the close | 0.97 | 0.96 | -0.7% |
| Aug 3, 2018 | After the close | 1.24 | 1.17 | -5.3% |
| May 4, 2018 | After the close | 1.28 | 1.21 | -5.5% |
| Feb 28, 2018 | After the close | 0.86 | 0.90 |
China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and…
| +4.0% |